V. Jehl

发表

Survival analysis for AdVerse events with VarYing follow‐up times (SAVVY): Rationale and statistical concept of a meta‐analytic study

K. Rufibach, T. Friede, C. Schmoor, 2019, Biometrical journal. Biometrische Zeitschrift.

Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)—estimation of adverse event risks

K. Rufibach, T. Friede, C. Schmoor, 2020, Trials.

Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer

Bruce E. Johnson, J. Soria, V. Papadimitrakopoulou, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up

M. Lebwohl, C. Griffiths, A. Deodhar, 2021, The British journal of dermatology.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non–small cell lung cancer

Michael Thomas, M. Brown, J. Schiller, 2013, Investigational New Drugs.

Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2016 .

Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.

F. Meric-Bernstam, James C Yao, A. Phan, 2013, Cancer research.

Everolimus inAdvancedPancreaticNeuroendocrineTumors : The Clinical Experience

F. Meric-Bernstam, James C Yao, A. Phan, 2013 .

Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.

J. Soria, V. Papadimitrakopoulou, B. Johnson, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial.

J. Hainsworth, E. Baudin, M. Pavel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M. Lebwohl, C. Griffiths, P. Primatesta, 2021, British Journal of Dermatology.

Comparison of adverse event risks in randomized controlled trials with varying follow-up times and competing events: Results from an empirical study

K. Rufibach, T. Friede, C. Schmoor, 2022, Statistics in Biopharmaceutical Research.

Comparison of Adverse Event Risks in Randomized Controlled Trials with Varying Follow-Up Times and Competing Events: Results from an Empirical Study

K. Rufibach, T. Friede, C. Schmoor, 2020, Statistics in Biopharmaceutical Research.

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

L. Kappos, A. Cross, H. Wiendl, 2022, Multiple sclerosis.

Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).

J. Soria, V. Papadimitrakopoulou, A. Jappe, 2010 .

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

J. Hainsworth, E. Baudin, James C Yao, 2011, The Lancet.

Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2.

S. Ricci, M. Pavel, R. Winkler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2017, The Lancet. Oncology.

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

M. Buyse, P. Hérait, P. Piedbois, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Cumulative Efficacy and Safety of 5-Year Deferasirox (Exjade®) Treatment in Pediatric Patients with Thalassemia Major: A Phase II Multicenter Prospective Trial

C. Rebischung, R. Galanello, A. Piga, 2008 .